Achieve Life Sciences, Inc.
QUIT- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000949858
No open-market purchases or sales by Achieve Life Sciences, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q3 2026; no superinvestor holds it.
Other share classesACHV
Key figures
- Market capClose on Nov 20, 2026
- $611.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026
- 0
- 13F valueReported value at the end of Q3 2026
- $0
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$54.6M
- No comparable prior period
- Free cash flow, FY2025
- -$49.5M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Superinvestors holding QUIT, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding QUIT at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Achieve Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 21, 2026 (view filing)4:30 PM ET | Aug 19 | 2 days | Stewart Richard AlistairDirector | SSale | −20.6K | $8.49 | −$175.2K | −9.0%208.2K after | |
| Sep 22, 2025 (view filing) | Sep 18 | 4 days | Oki Mark KChief Financial Officer | SSale | −50.1K | $2.92 | −$146.2K | −28.1%127.9K after | |
| Sep 22, 2025 (view filing) | Sep 18 | 4 days | Stewart Richard AlistairChief Executive Officer | SSale | −129.5K | $2.92 | −$378.1K | −36.1%228.9K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Wan JerryPrincipal Accounting Officer | SSale | −14.1K | $2.77 | −$39.0K | −30.1%32.7K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | King Thomas BraxtonDirector | SSale | −139.9K | $2.77 | −$387.4K | −30.7%315.1K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Jacobs CindyPresident & CMO | SSale | −27.6K | $2.77 | −$76.5K | −19.3%115.6K after | |
| Sep 8, 2025 (view filing) | Sep 4 | 4 days | Xinos JaimeChief Commercial Officer | SSale | −20.9K | $2.77 | −$57.8K | −21.9%74.4K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Oki Mark KChief Financial Officer | PPurchase | +10.0K | $2.89 | +$28.9K | New position10.0K after | |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Stewart Richard AlistairChieve Executive Officer | PPurchase | +10.0K | $2.86 | +$28.6K | +19.7%60.9K after | |
| Mar 6, 2024 (view filing) | Mar 4 | 2 days | Stewart Richard AlistairExecutive Chairman | PPurchase | +10.0K | $4.59 | +$45.9K | +35.1%38.5K after |
Top 10 13F holders, Q3 2026
View all: Top 10 13F holders, Q3 2026The largest institutional positions in Achieve Life Sciences, Inc. at the end of Q3 2026; share changes are against Q2 2026.
No institution reported holding QUIT in 13F filings for Q3 2026.